Jeanne Cunicelli has been named president of UPMC Enterprises succeeding Tal Heppenstall, who is retiring from UPMC after 17 years.
Cunicelli, who has led Enterprises’ Translational Sciences focus area since 2017, will take over on Jan. 1, 2021. She is a veteran venture capitalist in the life sciences industry, having been a managing director at Bay City Capital in San Francisco before joining UPMC.
Under Cunicelli’s leadership, the Translational Sciences team has grown to more than 20 scientific and investment professionals working to accelerate the transfer of scientific discoveries into life-changing medicines, diagnostics, and devices.
The team has formed five startup companies based on University of Pittsburgh research and is expanding its focus nationally and internationally to deploy $1 billion by 2024 in life sciences to grow their portfolio of syndicated investments alongside their company formation efforts. Collaborating with other leading venture capital firms, the team has participated in investment rounds for Werewolf Therapeutics and Cerevance.
Cunicelli, who will also become an executive vice president at UPMC, earned an MBA in finance from the University of San Francisco and a bachelor’s degree from Carnegie Mellon University, where she is currently a member of the board of trustees.
A Year in Review: A comprehensive look at UPMC Enterprises 2020
Over the last year, UPMC Enterprises, our portfolio companies, and select partners have all supported UPMC’s mission of Life Changing Medicine. In the booklet below, we have compiled highlights from a truly unique year and recognize the team members and projects that have enabled our success.
Writing a Fully Unit Testable Android App: The journey begins at the start of your project
Even as recently as API 30, the platform continues to evolve in this unfortunate direction, …
Machine Learning and Structural Bias in Health Care
In November 2020, the Center for Connected Medicine (CCM) convened a group of experts in …